U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C14H30O4S
Molecular Weight 294.451
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TETRADECYL HYDROGEN SULFATE (ESTER)

SMILES

CCCCC(CC)CCC(CC(C)C)OS(O)(=O)=O

InChI

InChIKey=GROJOWHVXQYQGN-UHFFFAOYSA-N
InChI=1S/C14H30O4S/c1-5-7-8-13(6-2)9-10-14(11-12(3)4)18-19(15,16)17/h12-14H,5-11H2,1-4H3,(H,15,16,17)

HIDE SMILES / InChI

Molecular Formula C14H30O4S
Molecular Weight 294.451
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. Sodium tetradecyl sulfate is the active component of the sclerosant drug Sotradecol. Sotradecol (sodium tetradecyl sulfate injection) is a sclerosing agent. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent. Sotradecol® (sodium tetradecyl sulfate injection) is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks. Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation. In the UK, Ireland, Italy, Australia, New Zealand and South Africa, it is sold under the trade-name Fibro-Vein in concentrations of 0.2%, 0.5%, 1.0%, and 3%

Originator

Curator's Comment: Sodium tetradecyl sulfate became widely used in the 1950s after its introduction in 1946 by Reiner.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SOTRADECOL

Approved Use

Sotradecol (sodium tetradecyl sulfate injection) is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks.

Launch Date

1946
PubMed

PubMed

TitleDatePubMed
Sclerosant treatment of varicose veins and deep vein thrombosis.
1984 Nov
[Cardiorespiratory arrest after injection of Trombovar (sodium tetradecyl sulfate)].
1993 Sep-Oct
Chronic facial pain following injection of sodium tetradecyl sulphate into an intraparotid haemolymphangioma.
2008 Sep
Inadvertent injection of sodium tetradecyl sulfate during placement of mental nerve block: discussion of management and outcome.
2009 Dec
Extensive muscle necrosis and infection following treatment of a lower extremity vascular malformation with Sotradecol and absolute ethanol.
2010 Jul
Patents

Sample Use Guides

Sotradecol (sodium tetradecyl sulfate injection) is for intravenous use only. The strength of solution required depends on the size and degree of varicosity. In general, the 1% solution will be found most useful with the 3% solution preferred for larger varicosities. The dosage should be kept small, using 0.5 mL to 2 mL (preferably 1 mL maximum) for each injection, and the maximum single treatment should not exceed 10 mL.
Route of Administration: Intravenous
In Vitro Use Guide
Sodium tetradecyl sulfate inhibited flagellation, motility, swarming, and growth of Proteus (inhibitory concentration, 0.1 to 0.5 mmoles per liter). At a concentration of 0.1 mmole per liter, sodium tetradecyl sulfate completely inhibited the motility of Proteus in the liquid medium employed without impairing growth.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:33:02 GMT 2023
Edited
by admin
on Fri Dec 15 16:33:02 GMT 2023
Record UNII
6326W0DRHY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TETRADECYL HYDROGEN SULFATE (ESTER)
Common Name English
TETRADECYL HYDROGEN SULFATE
Systematic Name English
7-ETHYL-2-METHYL-4-UNDECYL HYDROGEN SULFATE
Systematic Name English
TETRADECYL HYDROGEN SULPHATE
Systematic Name English
7-ETHYL-2-METHYL-4-UNDECANOL SULPHATE
Systematic Name English
7-ETHYL-2-METHYL-4-UNDECANOL SULFATE
Systematic Name English
TETRADECYL HYDROGEN SULPHATE (ESTER)
Common Name English
Code System Code Type Description
PUBCHEM
8771
Created by admin on Fri Dec 15 16:33:02 GMT 2023 , Edited by admin on Fri Dec 15 16:33:02 GMT 2023
PRIMARY
RXCUI
1370424
Created by admin on Fri Dec 15 16:33:02 GMT 2023 , Edited by admin on Fri Dec 15 16:33:02 GMT 2023
PRIMARY RxNorm
CHEBI
75275
Created by admin on Fri Dec 15 16:33:02 GMT 2023 , Edited by admin on Fri Dec 15 16:33:02 GMT 2023
PRIMARY
DAILYMED
6326W0DRHY
Created by admin on Fri Dec 15 16:33:02 GMT 2023 , Edited by admin on Fri Dec 15 16:33:02 GMT 2023
PRIMARY
CAS
300-52-7
Created by admin on Fri Dec 15 16:33:02 GMT 2023 , Edited by admin on Fri Dec 15 16:33:02 GMT 2023
PRIMARY
EPA CompTox
DTXSID7047015
Created by admin on Fri Dec 15 16:33:02 GMT 2023 , Edited by admin on Fri Dec 15 16:33:02 GMT 2023
PRIMARY
FDA UNII
6326W0DRHY
Created by admin on Fri Dec 15 16:33:02 GMT 2023 , Edited by admin on Fri Dec 15 16:33:02 GMT 2023
PRIMARY
DRUG BANK
DB11328
Created by admin on Fri Dec 15 16:33:02 GMT 2023 , Edited by admin on Fri Dec 15 16:33:02 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY